Genetically Modified Stem Cells Expressing Mutant CYP2B6 for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma, particularly in advanced stages, have limited efficacy and are associated with significant adverse reactions, leading to poor treatment adherence and suboptimal results, necessitating the development of new therapeutic approaches for effective and sustained cancer management.
Innovation Solution
Genetically modified human stem cells, specifically mesenchymal, induced pluripotent, or induced mesenchymal stem cells, engineered to express a mutant human cytochrome P450 2B6 protein and NADPH-cytochrome P450 reductase fusion protein, integrated into genomic safe harbors, capable of metabolizing cyclophosphamide and inducing immunological death of tumor cells, are used for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (Sorafenib, Regorafenib, Nivolumab) are used for advanced hepatocellular carcinoma, then some therapeutic effect is achieved, but significant adverse reactions occur leading to poor treatment adherence
Solution Approach 1:
The patent utilizes the harmful effect of cyclophosphamide (a cytotoxic drug) by engineering stem cells to express mutant CYP2B6* enzyme that activates cyclophosphamide specifically within tumor microenvironment. This converts a broadly toxic drug into a targeted therapeutic agent that kills tumor cells while sparing normal tissues, thereby maintaining efficacy while reducing adverse reactions
Solution Approach 2:
The patent introduces genetically modified stem cells as intermediary carriers that deliver and activate cyclophosphamide directly at the tumor site. These stem cells migrate to the tumor microenvironment and convert cyclophosphamide to its active form locally, acting as a mediator between the prodrug and tumor cells, thus achieving targeted therapy with reduced systemic toxicity
2Reliability
If current cancer therapies are administered, then tumor growth is inhibited to some extent, but treatment adherence deteriorates due to major adverse reactions
Solution Approach 1:
The patent transforms cyclophosphamide from a drug causing severe systemic toxicity into a targeted anti-tumor agent by using mutant CYP2B6* expressed in tumor-homing stem cells. This activation strategy converts a harmful broad-spectrum cytotoxic into a beneficial localized therapy, improving patient tolerance and adherence
Solution Approach 2:
The genetically modified stem cells autonomously migrate to the tumor microenvironment and self-activate cyclophosphamide through their expressed mutant CYP2B6* enzyme. This self-service mechanism eliminates the need for complex external activation protocols and ensures sustained localized therapy, thereby improving treatment adherence
3Reliability
If cyclophosphamide is activated by mutant CYP2B6* in genetically modified stem cells, then immunological death of tumor cells is induced, but the complexity of the treatment protocol increases
Solution Approach 1:
The genetically modified stem cells perform multiple functions: they migrate to tumors, express mutant CYP2B6* enzyme, activate cyclophosphamide, and induce immunological death of tumor cells. This multi-functionality consolidates several treatment steps into a single cellular therapy platform, reducing overall protocol complexity despite the sophisticated mechanism
Solution Approach 2:
The stem cells are pre-engineered ex vivo to express mutant CYP2B6* before administration. This preliminary genetic modification ensures that upon injection, the cells are immediately capable of activating cyclophosphamide at the tumor site, eliminating the need for complex in vivo activation protocols and simplifying the overall treatment approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The genetically modified stem cells effectively eradicate solid tumors, prevent recurrences, and protect against metastases by eliciting a strong antitumor immune response, offering a controlled and sustained therapeutic approach with reduced adverse effects.
Implementation Method 1
capable of metabolizing cyclophosphamide and inducing immunological death of the tumour cells by eliciting a strong antitumor immune response
Implementation Method 2
comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein and an NADPH-cytochrome P450 reductase protein
Data Source
AI summary
The present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into one of the genomic safe harbors of said human stem cell. The invention also relates to the use of said cell for the treatment of cancer and/or cancer recurrences and/or associated metastases, particularly the solid tumours, and in particular the hepatocellular carcinomas and/or associated metastases.